Cargando…
P62(dok), a Negative Regulator of Ras and Mitogen-Activated Protein Kinase (Mapk) Activity, Opposes Leukemogenesis by P210(bcr-abl)
p62(dok) has been identified as a substrate of many oncogenic tyrosine kinases such as the chronic myelogenous leukemia (CML) chimeric p210(bcr-abl) oncoprotein. It is also phosphorylated upon activation of many receptors and cytoplamic tyrosine kinases. However, the biological functions of p62(dok)...
Autores principales: | Di Cristofano, Antonio, Niki, Masaru, Zhao, Mingming, Karnell, Fredrick G., Clarkson, Bayard, Pear, Warren S., Van Aelst, Linda, Pandolfi, Pier Paolo |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
The Rockefeller University Press
2001
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2193466/ https://www.ncbi.nlm.nih.gov/pubmed/11489947 |
Ejemplares similares
-
Phosphoinositide 3-Kinase–Dependent Membrane Recruitment of P62(dok) Is Essential for Its Negative Effect on Mitogen-Activated Protein (Map) Kinase Activation
por: Zhao, Mingming, et al.
Publicado: (2001) -
Role of Dok-1 and Dok-2 in Leukemia Suppression
por: Niki, Masaru, et al.
Publicado: (2004) -
Effect of Ras Inhibition in Hematopoiesis and BCR/ABL Leukemogenesis
por: Baum, Karina J, et al.
Publicado: (2008) -
Contributions of the RhoGEF activity of p210 BCR/ABL to disease progression
por: Tala, Ilona, et al.
Publicado: (2012) -
p210(BCR‐ABL1)‐ Chronic myeloid leukemia presents with monocytosis
por: Wang, Xiaofei, et al.
Publicado: (2020)